结束阿尔茨海默病淀粉样蛋白降低疗法人体试验的伦理论证》。

Q1 Neuroscience AJOB Neuroscience Pub Date : 2024-04-01 Epub Date: 2022-10-05 DOI:10.1080/21507740.2022.2129858

Timothy Daly, Karl Herrup, Alberto J Espay

{"title":"结束阿尔茨海默病淀粉样蛋白降低疗法人体试验的伦理论证》。","authors":"Timothy Daly, Karl Herrup, Alberto J Espay","doi":"10.1080/21507740.2022.2129858","DOIUrl":null,"url":null,"abstract":"Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer's Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.","PeriodicalId":39022,"journal":{"name":"AJOB Neuroscience","volume":" ","pages":"80-81"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease.\",\"authors\":\"Timothy Daly, Karl Herrup, Alberto J Espay\",\"doi\":\"10.1080/21507740.2022.2129858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer's Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.\",\"PeriodicalId\":39022,\"journal\":{\"name\":\"AJOB Neuroscience\",\"volume\":\" \",\"pages\":\"80-81\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJOB Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21507740.2022.2129858\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJOB Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21507740.2022.2129858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Neuroscience","Score":null,"Total":0}

引用次数: 0

摘要

鉴于过去二十年来有 40 多项降低阿尔茨海默病（AD）淀粉样蛋白疗法的试验失败，其中许多试验都按设计成功地降低了淀粉样蛋白，我们提出了一个伦理论点，即清空降低淀粉样蛋白药物试验的药物管线，以结束降低淀粉样蛋白疗法在阿尔茨海默病中的历史主导地位。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer's Disease.

Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer's Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊